Who are you and what results, specifically, are you claiming are irreproducible?
It's ironic that the naysayers automatically invalidate the work of a world class scientist with an impeccable record because he has a company and therefore any conclusions he draws must be marred because of his vested interest. Yet you same people will take the word of a known short seller as gospel even though they have a proven track record for distorting the truth and outright lying.
@BassNBrew I don't have the time to argue with an "investor" whose position totals 40 shares. I suggest you sell them and take your best guy/gal out for a big night on the town. You'll never have to visit this thread again, and we will both be happier.
Ummm none of the trials have showed more effective than placebo.
The FDA has said regarding CD10...
"With the conclusion of both the CD10 and CD12 clinical trials, it has
become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was
no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints. "
The FDA on CD12...
"The larger trial that CytoDyn conducted in patients with severe COVID-19 disease (CD12)
also failed to find any effect of the drug on the primary study endpoint, with no difference seen in mortality (20.5% in the leronlimab treatment group and 21.6% in the placebo treatment group); or on any of the secondary endpoints, for example, with no difference on the average length of hospitalization (21.4 days in both the leronlimab and the placebo treatment groups)."
The FDA on subset populations...
"Subgroup analyses have well-established limitations, especially in the context of a clinical trial that has failed to show a benefit in the overall study population. For example, subgroups are often small, and therefore imbalances are common. Here, the data from CD12 illustrated imbalances in mortality among subgroups, some favoring leronlimab and some favoring placebo. None of these analyses met statistical significance when using established and reliable analytical methods that correct for multiple comparisons. However, as noted above, such analyses may inform the design of future clinical trials investigating leronlimab for the treatment of COVID-19. "
THESE ARE THE FDAs OWN WORDS!! NOT SHORT SELLERS.
So despite the peer reviewd MOA that Patterson believes in so much to have his company produce test for it......LL HAS NOT PROVEN EFFECTIVE IN THE REAL WORLD.
Your refusal to acknowledge that LL has not yet proven effective is delusional at this point and also screams like the opposite of a short....an insider pump. I hate saying that but that's truly what it's starting to sound like.